NEW YORK (GenomeWeb) – Evotec announced today that it has acquired a non-exclusive license to CRISPR-Cas9 genome-editing technology from the Broad Institute and Harvard University.

Under the terms of the deal, Evotec may use the technology for its drug-development and R&D activities, including in the development of research tools and in target identification, as well as to strengthen its post-phenotypical screening target deconvolution platform. 

Additional terms of the arrangement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.